Chief professor, School of Pharmaceutical Science and Technology

Academician,CAE

Researcher and project leader of Shanghai Institute of Materia Medica, and director of the Tumor Research Center

Dean, School of Pharmacy, UCAS

Long committed to research, development and personalized study on molecular targeted anti-tumor drugs,Dr. Dingis one of the main inventors of 14 new drug candidates with independent intellectual property rights now in clinical research phases I to III, among which six such new candidates are in clinical trials in the U.S. and Japan at the same time. More than 340 papers were published in the journals such asCell, Cancer Cell, Cell Res, HepatologyandNat Commun, with nearly 300 applied patents at home and abroad. He was awarded more than ten major prizes, including the second prize of the National Natural Science Award (2 awards), the second prize of the National Science and Technology Progress Award, a medal for the second National Innovation Pioneer Contest, the CAS Award for outstanding scientific and technological achievements, the Tan Jiazhen Award for achievements in life science.